RBS Australia 19/03/2010 1 Buy $37.50 4.7%
The broker continues to be impressed by the continued strong demand growth for IVIG in Europe and it sees CSL as a key beneficiary given it continues to develop new uses such as a treatment for Alzheimer's.
With no major changes to its forecasts following its latest review the broker retains its Buy rating and $37.50 price target.
- Forums
- ASX - By Stock
- CSL
- credit suisse - $40.50
credit suisse - $40.50, page-31
-
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$302.20 |
Change
-3.830(1.25%) |
Mkt cap ! $146.0B |
Open | High | Low | Value | Volume |
$302.89 | $302.89 | $299.73 | $79.51M | 263.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 276 | $302.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$302.20 | 5 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 237 | 302.190 |
4 | 21 | 302.180 |
5 | 70 | 302.170 |
1 | 24 | 302.150 |
8 | 83 | 302.140 |
Price($) | Vol. | No. |
---|---|---|
302.200 | 36 | 4 |
302.220 | 65 | 1 |
302.230 | 11 | 2 |
302.240 | 1 | 1 |
302.250 | 12 | 3 |
Last trade - 15.22pm 04/09/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |